Table 2.

Results of immunostaining for class III β-tubulin in tumors from 47 patients treated with taxane-based regimens and 44 patients treated with gemcitabine-based regimens and comparison between the two groups

% CellsPatients treated with taxane (%) n = 47Patients treated with gemcitabine (%) n = 44P
0–2416 (34)10 (22.7)0.23
25–496 (12.8)7 (15.9)0.67
50–746 (12.8)6 (13.6)0.9
75–10019 (40.4)21 (47.7)0.48